--- title: "A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection" type: "News" locale: "en" url: "https://longbridge.com/en/news/286784826.md" description: "Nurix Therapeutics (NRIX) has reported new data for its BTK degrader NX-5948 and secured a presentation at the EHA Congress. Despite a recent 9.45% decline in share price over the past month, the stock has a 66.72% return over the past year. Analysts view Nurix as overvalued with a P/S ratio of 22.8x, significantly above peers. The company is currently unprofitable with a net loss of $295.28 million, raising concerns about future profitability amidst high revenue growth expectations." datetime: "2026-05-18T14:05:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286784826.md) - [en](https://longbridge.com/en/news/286784826.md) - [zh-HK](https://longbridge.com/zh-HK/news/286784826.md) --- # A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection Nurix Therapeutics (NRIX) is back in focus after reporting new preclinical and Phase 1 data for its BTK degrader NX-5948, and after securing an oral presentation slot at the European Hematology Association Congress. See our latest analysis for Nurix Therapeutics. Despite the recent NX-5948 data and the upcoming European Hematology Association presentation, Nurix Therapeutics’ share price has eased over the past month, with a 30 day share price return of 9.45% down, even as the 1 year total shareholder return sits at 66.72%. This suggests that long term momentum has been stronger than the latest pullback. If Nurix’s pipeline has caught your attention, this could be a good moment to see what else is moving in the sector by scanning 28 healthcare AI stocks With the stock down over the past month but still showing strong 1 year and 3 year total returns, the key question now is whether Nurix is temporarily out of favor or if the market already reflects its future potential. ## Preferred Price-to-Sales of 22.8x: Is it justified? On a P/S basis, Nurix looks expensive, with a ratio of 22.8x that sits above both its peers and what Simply Wall St’s fair multiple model suggests. The price to sales ratio compares the company’s market value to its revenue, which is a common reference point for biotech stocks that are still loss making. For Nurix, analysts expect revenue to grow at 42.2% per year, yet the company is currently unprofitable, reports a loss of $295.28m, and is forecast to remain loss making over the next three years. That combination, a high P/S multiple, ongoing losses, and forecasts that do not point to near term profitability, implies that a lot of optimism is already reflected in the share price. Nurix is also viewed as expensive relative to a fair price to sales estimate of 0x. Its P/S is above both the peer average of 17x and the wider US biotech industry average of 10.6x, a gap the market could reassess if sentiment shifts. Explore the SWS fair ratio for Nurix Therapeutics **Result: Price-to-Sales of 22.8x (OVERVALUED)** However, you also need to weigh the risk that high revenue growth expectations and ongoing losses, including a US$295.28m net loss, may be too optimistic. Find out about the key risks to this Nurix Therapeutics narrative. ## Next Steps Sentiment around Nurix is mixed, with clear risks on one side and meaningful potential rewards on the other. It makes sense to review the data yourself and decide how comfortable you are with that trade off by checking the 2 key rewards and 2 important warning signs ## Looking for more investment ideas? If you are serious about building a stronger portfolio, this is the moment to widen your search and see what other opportunities are already on Simply Wall St. - Target potential value opportunities early by scanning 51 high quality undervalued stocks before the rest of the market takes notice. - Steady your portfolio with companies that prioritize balance sheet strength using the solid balance sheet and fundamentals stocks screener (45 results). - Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems that combine quality fundamentals with lower market attention. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Related Stocks - [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) ## Related News & Research - [Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)](https://longbridge.com/en/news/286587770.md) - [vTv Therapeutics posts Q1 profit on license payment](https://longbridge.com/en/news/286309828.md) - [HC Wainwright Analysts Increase Earnings Estimates for CTMX](https://longbridge.com/en/news/286258226.md) - [GRI Bio Highlights Promising Phase 2a IPF Data, Outlook](https://longbridge.com/en/news/286422240.md) - [](https://longbridge.com/en/news/286273737.md)